TMEM

A novel breast cancer dissemination marker for the assessment of metastatic risk

Maja H. Oktay, Joan G. Jones

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

MyCartis NV, a new player on the clinical and translational research market, aims at revolutionizing current healthcare systems. These are mostly based on treating the diseased rather than on caring better and longer for the healthy. The one size fits all model is no longer sufficient and is unsustainable in the long run. Although it comes very scattered, todays access to molecular information has the potential to make healthcare more personal and effective, shifting it from treating diseases to improving quality of life. MyCartis wants to contribute to this process by developing broadly available next generation multiplex biomarker analysis solutions both at the technical and content levels. The EvalutionTM platform provides a one technology fits all solution to enable researchers to validate their biomarkers and assay providers to utilize them, no matter their physical nature: multiplexing in its true sense. The ability to quantify different types of markers on a single platform will help produce more comprehensive and coherent multiplex datasets, which will facilitate the integration into syndromic assay formats.

Original languageEnglish (US)
Pages (from-to)81-84
Number of pages4
JournalBiomarkers in Medicine
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Biomarkers
Assays
Breast Neoplasms
Delivery of Health Care
Access to Information
Aptitude
Translational Medical Research
Multiplexing
Quality of Life
Research Personnel
Technology
Datasets

Keywords

  • Breast cancer
  • Metastases
  • Prognostic markers
  • Tumor microenvironment

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

TMEM : A novel breast cancer dissemination marker for the assessment of metastatic risk. / Oktay, Maja H.; Jones, Joan G.

In: Biomarkers in Medicine, Vol. 9, No. 2, 01.02.2015, p. 81-84.

Research output: Contribution to journalArticle

@article{9aae6f4ded894bc8aa7d8f1bb479f848,
title = "TMEM: A novel breast cancer dissemination marker for the assessment of metastatic risk",
abstract = "MyCartis NV, a new player on the clinical and translational research market, aims at revolutionizing current healthcare systems. These are mostly based on treating the diseased rather than on caring better and longer for the healthy. The one size fits all model is no longer sufficient and is unsustainable in the long run. Although it comes very scattered, todays access to molecular information has the potential to make healthcare more personal and effective, shifting it from treating diseases to improving quality of life. MyCartis wants to contribute to this process by developing broadly available next generation multiplex biomarker analysis solutions both at the technical and content levels. The EvalutionTM platform provides a one technology fits all solution to enable researchers to validate their biomarkers and assay providers to utilize them, no matter their physical nature: multiplexing in its true sense. The ability to quantify different types of markers on a single platform will help produce more comprehensive and coherent multiplex datasets, which will facilitate the integration into syndromic assay formats.",
keywords = "Breast cancer, Metastases, Prognostic markers, Tumor microenvironment",
author = "Oktay, {Maja H.} and Jones, {Joan G.}",
year = "2015",
month = "2",
day = "1",
doi = "10.2217/BMM.14.104",
language = "English (US)",
volume = "9",
pages = "81--84",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - TMEM

T2 - A novel breast cancer dissemination marker for the assessment of metastatic risk

AU - Oktay, Maja H.

AU - Jones, Joan G.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - MyCartis NV, a new player on the clinical and translational research market, aims at revolutionizing current healthcare systems. These are mostly based on treating the diseased rather than on caring better and longer for the healthy. The one size fits all model is no longer sufficient and is unsustainable in the long run. Although it comes very scattered, todays access to molecular information has the potential to make healthcare more personal and effective, shifting it from treating diseases to improving quality of life. MyCartis wants to contribute to this process by developing broadly available next generation multiplex biomarker analysis solutions both at the technical and content levels. The EvalutionTM platform provides a one technology fits all solution to enable researchers to validate their biomarkers and assay providers to utilize them, no matter their physical nature: multiplexing in its true sense. The ability to quantify different types of markers on a single platform will help produce more comprehensive and coherent multiplex datasets, which will facilitate the integration into syndromic assay formats.

AB - MyCartis NV, a new player on the clinical and translational research market, aims at revolutionizing current healthcare systems. These are mostly based on treating the diseased rather than on caring better and longer for the healthy. The one size fits all model is no longer sufficient and is unsustainable in the long run. Although it comes very scattered, todays access to molecular information has the potential to make healthcare more personal and effective, shifting it from treating diseases to improving quality of life. MyCartis wants to contribute to this process by developing broadly available next generation multiplex biomarker analysis solutions both at the technical and content levels. The EvalutionTM platform provides a one technology fits all solution to enable researchers to validate their biomarkers and assay providers to utilize them, no matter their physical nature: multiplexing in its true sense. The ability to quantify different types of markers on a single platform will help produce more comprehensive and coherent multiplex datasets, which will facilitate the integration into syndromic assay formats.

KW - Breast cancer

KW - Metastases

KW - Prognostic markers

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84923436512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923436512&partnerID=8YFLogxK

U2 - 10.2217/BMM.14.104

DO - 10.2217/BMM.14.104

M3 - Article

VL - 9

SP - 81

EP - 84

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 2

ER -